Interest of Eosinopia in the Diagnosis of Infection in the Emergency Department

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03467672

Acronym

SEPSISEO

Enrollment

2000

Registered

2018-03-16

Start date

2018-03-23

Completion date

2020-03-31

Last updated

2019-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eosinopenia

Brief summary

Several studies have described the interest of eosinopenia as a marker of infection in internal medicine or in intensive care units. Eosinopenia is an inexpensive and easily accessible biological marker of sepsis. Retrospective work in the adult emergency departments of Strasbourg University Hospitals has shown the good specificity of this biological sign for the diagnosis of infection. Our work aims to confirm the results by a more meaningful study. Main objective: Evaluation of the interest of eosinopenia in the diagnosis of bacterial infection in ED. Methodology: inclusion of all patients with criteria for bacterial infection in ED, inclusion of an equivalent number of uninfected control patients. Duration : 12 months Multicentric prospective study 6 centers : Strasbourg, Hôpital Nord Franche comté, Sélestat, Wissembourg, Colmar, Mulhouse

Interventions

OTHERDiagnosis of bacterial infection

use of eosinopenia in the diagnosis of bacterial infection

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* major patient * patient suspected of infection and benefiting from the routine practice of NFS, whatever the indication during his / her visit to the emergency room. * patient with or without criteria for bacterial infection * patient affiliated to a social security scheme * patient (or legal representative) who has agreed to participate in the study

Exclusion criteria

* anti tumor chemotherapy * immunosuppressive treatment * corticotherapy * antibiotherapy in progress * malignant hemopathy * evolutionary cancer * refusal to participate in the study * subjects under safeguard of justice * subject under guardianship or curatorship

Design outcomes

Primary

Measure	Time frame	Description
eosinopenia as a sepsis marker	102 month	Evaluation of the interest of eosinopenia in the diagnosis of infectious states in emergencies.

Countries

France

Contacts

Primary ContactCharles-Eric Dr. LAVOIGNET

Charles-eric.lavoignet@hnfc.fr03 84 98 33 97

Backup ContactPascal BILBAULT

Pascal.Bilbault@chru-strasbourg.fr03 88 12 86 82

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026